Novoprotein(SH:688137)2025-02-27 10:50Financial Performance - Total revenue for 2024 was CNY 127.45 million, a decrease of 16.81% compared to the previous year[2] - Net profit attributable to shareholders of the parent company was CNY -54.81 million, a decline of 526.72% year-on-year[2] - Basic earnings per share decreased to CNY -0.78, down 533.33% from CNY 0.18 in the previous year[2] Assets and Equity - Total assets at the end of the reporting period were CNY 2,212.84 million, a decrease of 3.74% from the beginning of the period[4] - Shareholders' equity attributable to the parent company was CNY 2,101.29 million, down 3.98% from the beginning of the period[4] Business Strategy and Development - The company is focusing on enhancing its product lines in protein, cytokines, recombinant antibodies, enzymes, and reagents[8] - Increased investment in quality improvement and R&D has negatively impacted net profit due to higher expenses[8] - The company is expanding its marketing team and enhancing brand marketing to increase market share[8] Market Conditions - The decline in gross profit margin was attributed to intensified market competition and increased expenses related to new business development[9] - The company conducted impairment tests on assets showing signs of impairment, following prudent accounting principles[8]